Adaptimmune Therapeutics (ADAP)

Executive Summary

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. More Details


Revenue is forecast to grow 70.36% per year

Risk Analysis

Earnings are forecast to decline by an average of 11.8% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

+ 1 more risk

Snowflake Analysis

Flawless balance sheet with limited growth.

Similar Companies

Search for a company to compare.